Beyond the Needle: GLP-1 Receptor Agonists and Dual Incretin Agonists in Obesity and Cardiometabolic Disease — Clinical Benefits, Safety Signals and the Expanding Role of Nursing — A Narrative Review
Health Innovation Reports · 15.10.2026 · 2 (4) · 25-33
DOI: 10.64048/hir.v2n4.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Innovation Reports, online erschienen am 15.10.2026. Verfasst von Hardi Abdulqadir Hasan und 1 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist tirzepatide have transformed the treatment of type 2 diabetes and obesity, and their indications now extend to cardiovascular, renal, liver and sleep-related disease. Their rapid uptake has placed nurses at the centre of initiation, titration, education, monitoring and long-term follow-up, yet nursing roles are seldom described in the literature. This narrative review synthesises the published evidence on these medicines from a nursing perspective. The burden of obesity and the evolving concept of clinical obesity are first outlined, followed by the mechanisms of action of incretin-based therapies. The evidence from landmark trials on weight, glycaemic, cardiovascular, kidney, heart failure, sleep apnoea and liver outcomes is then examined. The principal safety concerns are described in an integrated manner, including gastrointestinal effects, dehydration, pancreatobiliary events, peri-procedural aspiration, loss of lean mass, emerging signals and weight regain after discontinuation, together with nursing assessment and actions for each. Finally, a phase-based framework for nursing care, implementation challenges such as equity of access and weight stigma, and priorities for nursing research are considered. By linking pharmacology and trial evidence with practical nursing responsibilities, this review offers a conceptual framework and a practical reference for nurses, educators, managers and policymakers. In sum, the work positions nursing as essential to the safe, equitable and sustained use of incretin-based therapies.
Zitieren
APA
Hasan, H. A., & Saleh, J. H. (2026). Beyond the Needle: GLP-1 Receptor Agonists and Dual Incretin Agonists in Obesity and Cardiometabolic Disease — Clinical Benefits, Safety Signals and the Expanding Role of Nursing — A Narrative Review. Health Innovation Reports, 2(4), 25-33. https://doi.org/10.64048/hir.v2n4.004
Vancouver
Hasan HA, Saleh JH. Beyond the Needle: GLP-1 Receptor Agonists and Dual Incretin Agonists in Obesity and Cardiometabolic Disease — Clinical Benefits, Safety Signals and the Expanding Role of Nursing — A Narrative Review. Health Innovation Reports. 2026;2(4):25-33. doi:10.64048/hir.v2n4.004
BibTeX
@article{Hasan2026,
author = {Hasan, Hardi Abdulqadir and Saleh, Jihad Haji},
title = {Beyond the Needle: GLP-1 Receptor Agonists and Dual Incretin Agonists in Obesity and Cardiometabolic Disease — Clinical Benefits, Safety Signals and the Expanding Role of Nursing — A Narrative Review},
journal = {Health Innovation Reports},
year = {2026},
volume = {2},
number = {4},
pages = {25--33},
doi = {10.64048/hir.v2n4.004}
}
EUVIMED